Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 juil. 2018 08h00 HE | Source: Cue Biopharma, Inc.

Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck

CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human...
28 juin 2018 09h15 HE | Source: Cue Biopharma, Inc.

Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee

CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to...
10 mai 2018 08h00 HE | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Investor Business Update Call and Webcast

CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively...
25 avr. 2018 08h00 HE | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer

CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
05 avr. 2018 08h00 HE | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at Bloomberg Biotech Innovations Conference

CAMBRIDGE, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate...